PRGN-3005 UltraCAR-T cells for Fallopian Tube Cancer

Fred Hutch/University of Washington Cancer Consortium, Seattle, WA
Fallopian Tube Cancer+33 More ConditionsPRGN-3005 UltraCAR-T cells - Biological
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment that uses modified immune cells to target and kill ovarian cancer cells.

Eligible Conditions
  • Stage IVB Primary Peritoneal Cancer
  • Stage IIIB Primary Peritoneal Cancer
  • Stage IIIC Fallopian Tube Cancer
  • Platinum-Resistant Fallopian Tube Carcinoma
  • Refractory Fallopian Tube Carcinoma
  • Stage IIIA Primary Peritoneal Cancer
  • Stage III Fallopian Tube Cancer
  • Stage III Primary Peritoneal Cancer
  • Stage IIIC Primary Peritoneal Cancer
  • Stage IV Primary Peritoneal Cancer
  • Stage IVA Primary Peritoneal Cancer
  • Stage IVA Fallopian Tube Cancer
  • Stage IIIB Fallopian Tube Cancer
  • Recurrent Fallopian Tube Cancer
  • Stage IV Fallopian Tube Cancer
  • Stage IIIA1 Fallopian Tube Cancer
  • Stage IIIA Fallopian Tube Cancer
  • Stage IVA Ovarian Cancer
  • Stage IIIA2 Fallopian Tube Cancer
  • Refractory Ovarian Cancer
  • Platinum-resistant Ovarian Cancer
  • Stage III Ovarian Cancer
  • Stage IIIA1 Ovarian Cancer
  • Stage IV Ovarian Cancer
  • Recurrent Primary Peritoneal Carcinoma
  • Stage IVB Fallopian Tube Cancer
  • Stage IVB Ovarian Cancer
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Ovarian Cancer
  • Refractory Primary Peritoneal Carcinoma
  • Stage IIIB Ovarian Cancer
  • Stage IIIA2 Ovarian Cancer
  • Stage IIIA Ovarian Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Up to 5 years

Month 12
Incidence of adverse events
Month 12
Number of PRGN-3005 T Cells
Up to 28 days
Maximal tolerated dose of PRGN-3005
Up to 5 years
Evidence of anti-tumor activity

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Treatment (PRGN-3005 UltraCAR-T cells) IP Administration
1 of 2
Treatment (PRGN-3005 UltraCAR-T cells) IV Administration
1 of 2

Experimental Treatment

71 Total Participants · 2 Treatment Groups

Primary Treatment: PRGN-3005 UltraCAR-T cells · No Placebo Group · Phase 1

Treatment (PRGN-3005 UltraCAR-T cells) IP Administration
Biological
Experimental Group · 1 Intervention: PRGN-3005 UltraCAR-T cells · Intervention Types: Biological
Treatment (PRGN-3005 UltraCAR-T cells) IV Administration
Biological
Experimental Group · 1 Intervention: PRGN-3005 UltraCAR-T cells · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Precigen, IncLead Sponsor
4 Previous Clinical Trials
236 Total Patients Enrolled
PGEN Therapeutics, Inc., a subsidiary of Precigen, Inc.Lead Sponsor
2 Previous Clinical Trials
136 Total Patients Enrolled
Amy R. Lankford, PhDStudy DirectorPrecigen, Inc
1 Previous Clinical Trials
88 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is there an open call for participants in this trial?

"Evidenced by the clinicaltrials.gov page, this trial is currently open to participants. The medical experiment was initiated on April 30th 2019 and its details were most recently updated as of June 28th 2022." - Anonymous Online Contributor

Unverified Answer

What potential adverse effects could arise from the use of PRGN-3005 UltraCAR-T cells?

"The safety of PRGN-3005 UltraCAR-T cells is deemed to be a 1 on the scale, as this phase one trial only has limited data that supports its efficacy and security." - Anonymous Online Contributor

Unverified Answer

What is the total sample size for this medical trial?

"Affirmative. According to clinicaltrials.gov, the research study went live on April 30th 2019 and was last revised on June 28th 2022. 71 individuals are being recruited from one medical centre for this trial." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.